These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 20370686

  • 1. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
    Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, Goustin AS, Almhanna K, Yang D, Sarkar FH, Mohammad RM.
    Curr Cancer Drug Targets; 2010 May; 10(3):319-31. PubMed ID: 20370686
    [Abstract] [Full Text] [Related]

  • 2. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.
    Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM.
    Eur J Cancer; 2010 Apr; 46(6):1122-31. PubMed ID: 20156675
    [Abstract] [Full Text] [Related]

  • 3. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
    Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, Liu M, Wang G, Lu Y, McEachern D, Bernard D, Bradford CR, Carey TE, Wang S.
    Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
    [Abstract] [Full Text] [Related]

  • 4. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D, Lin J.
    Br J Cancer; 2009 Sep 01; 101(5):774-81. PubMed ID: 19707204
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
    Saxena R, Gupta G, Manohar M, Debnath U, Popli P, Prabhakar YS, Konwar R, Kumar S, Kumar A, Dwivedi A.
    Int J Biochem Cell Biol; 2016 Jan 01; 70():105-17. PubMed ID: 26556313
    [Abstract] [Full Text] [Related]

  • 10. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B, Bendinelli S, Gabelloni P, Da Pozzo E, Daniele S, Scatena F, Vanacore R, Campiglia P, Bertamino A, Gomez-Monterrey I, Sorriento D, Del Giudice C, Iaccarino G, Novellino E, Martini C.
    PLoS One; 2013 Jan 01; 8(8):e72281. PubMed ID: 23977270
    [Abstract] [Full Text] [Related]

  • 11. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD, Kees UR, Tweddle DA, Lunec J.
    Oncogene; 2012 Feb 09; 31(6):752-63. PubMed ID: 21725357
    [Abstract] [Full Text] [Related]

  • 12. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T, Wang J, Chen X, Meng X, Song X, Lu Z, Jiang H, Liu L.
    Tumour Biol; 2010 Aug 09; 31(4):287-95. PubMed ID: 20422343
    [Abstract] [Full Text] [Related]

  • 13. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
    Wang S, Sun W, Zhao Y, McEachern D, Meaux I, Barrière C, Stuckey JA, Meagher JL, Bai L, Liu L, Hoffman-Luca CG, Lu J, Shangary S, Yu S, Bernard D, Aguilar A, Dos-Santos O, Besret L, Guerif S, Pannier P, Gorge-Bernat D, Debussche L.
    Cancer Res; 2014 Oct 15; 74(20):5855-65. PubMed ID: 25145672
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
    Lotfy G, Abdel Aziz YM, Said MM, El Ashry ESH, El Tamany ESH, Abu-Serie MM, Teleb M, Dömling A, Barakat A.
    Bioorg Chem; 2021 Dec 15; 117():105427. PubMed ID: 34794098
    [Abstract] [Full Text] [Related]

  • 17. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ, Vega F, Medeiros LJ.
    Leukemia; 2011 May 15; 25(5):856-67. PubMed ID: 21394100
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
    Liu QJ, Shen HL, Lin J, Xu XH, Ji ZG, Han X, Shang DH, Yang PQ.
    Drug Des Devel Ther; 2016 May 15; 10():745-55. PubMed ID: 26937175
    [Abstract] [Full Text] [Related]

  • 20. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy.
    Azmi AS, Philip PA, Beck FW, Wang Z, Banerjee S, Wang S, Yang D, Sarkar FH, Mohammad RM.
    Oncogene; 2011 Jan 06; 30(1):117-26. PubMed ID: 20818437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.